Europe Overactive Bladder Treatment Market

The Europe overactive bladder treatment market is expected to grow from US$ 1,111.05 million in 2022 to US$ 1,318.55 million by 2028; it is estimated to grow at a CAGR of 2.9% from 2022 to 2028.

Growing Incidence of Urinary Tract Infections Fuels Europe Overactive Bladder Treatment Market Growth

Urinary tract infection (UTI) may lead to increased activity in the bladder wall muscles, causing symptoms similar to an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities can further damage the integrity of the urothelial barrier. UTI is the eighth and fifth most common reason for ambulatory clinic visits and emergency department visits, respectively, in the country. Moreover, as per the National Institute for Health and Care Excellence organization, UTIs are among the most common hospital-acquired infections in the UK, accounting for ~23% of all infections. According to the BMC Family Practice, UTI consultations accounted for ~2% of ED visits in the Netherlands in 2019. Similarly, in France, ~4–6 million people suffer from UTI each year. Thus, the increasing incidence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the Europe overactive bladder treatment market growth.    

Europe Overactive Bladder Treatment Market Overview

The Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global overactive bladder treatment market and is estimated to register a substantial CAGR over the forecast period. The growing demand for overactive bladder treatment due to the presence of the geriatric population is driving the market growth in Europe. Further, the prevalence of neurological diseases and diabetes hampering urinary tract functions is likely to create opportunities for the growth of overactive bladder treatment in the coming years. According to the UK Parliament’s data, approximately one-fifth of the total UK population was aged 65 and above in 2019. Besides, the number of people in this age group increased by 23% from 2009 to 2019, while the total UK population increased by only 7% during the same period. Diabetes UK states that ~3.9 million people were diagnosed with diabetes in 2019, and it reached 4.7 million in 2021. The rising prevalence of diabetes and the growing elderly population in the UK lead to surging cases of overactive bladder condition, thereby stroking the demand for its treatment.

Europe Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)

Europe Overactive Bladder Treatment Strategic Insights

Strategic insights for the Europe Overactive Bladder Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Overactive Bladder Treatment Report Scope

Europe Overactive Bladder Treatment Regional Insights

The geographic scope of the Europe Overactive Bladder Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe Overactive Bladder Treatment Market Segmentation

The Europe overactive bladder treatment market is segmented into pharmacotherapy, disease type, and country.

The Europe overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

• Based on pharmacotherapy, the market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.
• Based on disease type, the Europe overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.
• Based on country, the Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the market in 2022.  

AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the overactive bladder treatment market in Europe.